Back to top
more

Arcellx (ACLX)

(Real Time Quote from BATS)

$71.44 USD

71.44
46,126

+0.30 (0.42%)

Updated Aug 4, 2025 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of -34.52% and 55.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of -38.10% and 44.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kinjel Shah headshot

5 Biotech Breakthrough Stocks to Watch in 2025

by Kinjel Shah

It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice

by Zacks Equity Research

Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of 11.11% and 26.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 101.59% and 47.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?

by Zacks Equity Research

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of 5.56% and 1.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alkermes (ALKS) Lags Q2 Earnings Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of -1.37% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How Arcellx (ACLX) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

by Zacks Equity Research

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

Zacks Equity Research

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

by Zacks Equity Research

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.

Zacks Equity Research

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

by Zacks Equity Research

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Zacks Equity Research

Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?

by Zacks Equity Research

Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

by Ekta Bagri

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Zacks Equity Research

Roblox (RBLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Roblox's (RBLX) third-quarter 2023 performance is expected to have benefited from growth in engagement hours and daily active users.